Overview

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

Status:
Completed
Trial end date:
2015-04-20
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies, Monoclonal